Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled ferumoxytol trial in iron deficiency anemia
2011-001865-42Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Jul 2011
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Ferumoxytol with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving ≥2.0 g/dL increase in hemoglobin. Started Jul 2011; status: completed.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2011-001865-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001865-42.